RGLS: Regulus Therapeutics Inc Analyst Target Range

Regulus Therapeutics (RGLS) develops advanced miRNA-based drugs to combat renal pathologies, where patent longevity ensures a stable revenue stream. The company's environmental development vector mandates the implementation of "green chemistry" and the optimization of center energy consumption. The confirmed price history on this chart reflects a value of 6.98. Meanwhile, the production of oligonucleotides for medical tests has been delegated to specialized external contractors.

Regulus Therapeutics Inc. - RGLS Price Target Chart (period 07/04/2022 - 07/05/2025)

Metric breakdowns and analytics for Regulus Therapeutics Inc (RGLS)

- share price and consensus valuation forecast:

Price Performance Chart regulusrx.com|RGLS - Analyst Consensus Forecast

- market capitalization information:

Market Capitalization Regulus Therapeutics Inc|RGLS - Total Company Value

- book capitalization data:

Net Assets per Single Share Regulus Therapeutics|RGLS - Company Book Value|Market Capitalization to Book Value regulusrx.com|RGLS - Company Total Assets

- issuer credit burden and liquidity indicators:

- financial results and valuation multiples details:

RGLS - Net Profit|Projected Net Profit Regulus Therapeutics|RGLS - Price to Earnings Ratio|Forward P/E Multiple Regulus Therapeutics, Inc.|RGLS - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Regulus Therapeutics Inc|RGLS - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Regulus Therapeutics|RGLS - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months regulusrx.com|RGLS - Net earnings per share growth this year|Expected earnings per share trend next year Regulus Therapeutics

General company analysis:RGLS regulusrx.com

This indicator aggregates expert market expectations for the fair value of shares, comparing them with US industry medians to identify business valuation skews. Analyzing the consensus target price trend allows investors to gauge market confidence in Regulus Therapeutics (RGLS), which is currently bolstered by the stability of its R&D core and the recruitment of regulatory specialists to ensure the successful completion of clinical trials.

Competitors of Regulus Therapeutics